Research programme: biglycan therapeutics - Pharmahungary

Drug Profile

Research programme: biglycan therapeutics - Pharmahungary

Alternative Names: Biglycan™ therapy - Pharmahungary

Latest Information Update: 05 Jul 2016

Price : $50

At a glance

  • Originator Pharmahungary Group
  • Class Proteoglycans
  • Mechanism of Action Proteoglycan stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Atherosclerosis; Myocardial infarction

Most Recent Events

  • 05 Jul 2016 Preclinical trials in Myocardial infarction in Hungary (unspecified route)
  • 05 Jul 2016 Preclinical trials in Atherosclerosis in Hungary (unspecified route)
  • 05 Jul 2016 Research programme: biglycan therapeutics - Pharmahungary is available for licensing - http://www.pharmahungary.com/in-house-r-d-projects
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top